GET DAILY SIGNALSEli Lilly (LLY) vs Merck (MRK): +39% Revenue Growth Highlights Diverging Paths
Key Takeaways
- LLY reported quarterly revenue growth of roughly 39% year over year, while MRK posted about 5% growth, highlighting a sharp divergence in near-term momentum.
- LLY raised its full-year revenue guidance for the third time this year, whereas MRK delivered a more modest guidance increase alongside a year-over-year earnings decline.
- Tickeron AI Verdict: LLY is currently favored over MRK, reflecting stronger trend consistency, superior growth momentum, and more visible near-term catalysts.
- MRK trades as a more diversified, value-oriented pharmaceutical name but carries concentration risk tied to the 2028 U.S. patent expiry of its flagship Keytruda franchise.
- For deeper context, explore LLY Major News and LLY Today's Price Move, as well as MRK Major News and MRK Today's Price Move.
- To see how automated strategies are positioning across the market, explore Trending AI Robots.
Setting the Stage for Two Pharma Leaders
Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) rank among the largest pharmaceutical companies, yet they occupy distinct stages in their growth trajectories. This comparison matters for investors balancing high-growth momentum against a steadier, income-focused profile. Both released quarterly results around the same time, offering a useful window to evaluate their performance, positioning, and risks together. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
LLY’s Recent Momentum and Drivers
Eli Lilly has emerged as the world’s most valuable pharmaceutical firm, with a market capitalization above $1 trillion, fueled largely by its GLP-1 franchise for diabetes and obesity. In the latest quarter, LLY posted revenue near $24.4 billion, a 39% year-over-year increase, and raised full-year revenue guidance for the third time to a range of $91 billion to $92 billion. Mounjaro delivered roughly $10.7 billion in quarterly sales, while Zepbound added about $5.4 billion.
Supportive factors include sustained demand, expanded Medicare coverage for weight-loss therapies, and encouraging data on retatrutide. The stock has climbed to new highs recently, even after its oral candidate orforglipron fell short of some expectations. Management adjusted EPS guidance modestly lower due to acquisition costs, but this did little to alter the overall positive outlook.
MRK’s Steady but Slower Profile
Merck operates as a diversified player across pharmaceuticals and animal health, with near-term results still centered on Keytruda, the top-selling cancer treatment. The most recent quarter showed revenue of approximately $18.1 billion, up 5% year over year, though adjusted EPS fell to $2.49. The company raised the midpoint of its full-year outlook and improved its adjusted EPS target, helped by oncology strength and newer offerings such as Winrevair and the subcutaneous Keytruda Qlex formulation.
Focus remains on the 2028 U.S. patent expiration for intravenous Keytruda and the shift toward Qlex. Additional attention has gone to its investigational cancer vaccine with Moderna. Year-to-date performance has been solid, yet the growth pace stays more measured than LLY’s.
Head-to-Head: Growth Concentration vs Diversification
The main distinction lies in concentrated growth versus broader exposure. LLY centers much of its momentum on GLP-1 therapies, delivering strong revenue gains and repeated guidance lifts, though this leaves it exposed to pricing pressures, competition from Novo Nordisk, and oral-product rollout risks. MRK spans oncology, vaccines, cardiovascular, and animal health for a wider revenue base and more value-oriented valuation, but faces slower expansion, legacy product erosion such as Januvia and Bridion, and the upcoming Keytruda patent challenge.
Momentum favors LLY with accelerating revenue and multiple upward revisions. MRK has seen Gardasil recovery and early Qlex uptake, offset by higher R&D spending. Risk profiles also differ: LLY contends with valuation and concentration concerns, while MRK faces patent-expiry and pipeline risks.
AI Framework Assessment
Considering trend consistency, relative momentum, growth durability, and catalyst visibility, Tickeron’s AI framework currently favors LLY over MRK. LLY shows a stronger, more sustained uptrend supported by revenue acceleration and guidance increases, while MRK offers steadier but slower growth with greater uncertainty around Keytruda. This view represents a momentum-oriented, probabilistic comparison rather than a fixed forecast, and conditions can evolve.
Exploring Automated Strategies
From what I see, reviewing current automated approaches can add useful perspective on how different market regimes are being navigated. I checked Tickeron’s AI Daily Buy/Sell Signals to gauge broader positioning alongside these two names.
Personal Take on Tickeron’s AI Tools
I often turn to Tickeron’s platform when comparing names like these, and the AI Screener has proven especially helpful for quickly spotting relative strength and industry context without sifting through endless data. It fits naturally into my routine for validating momentum signals before digging deeper into fundamentals or news flow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LLY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LLY turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 48 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 232 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for LLY moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 25 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
LLY broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (33.895) is slightly higher than the industry average of (-2.729). P/E Ratio (43.159) is within average values for comparable stocks, (20.997). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.040) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement